See more : Monument Circle Acquisition Corp. (MONCU) Income Statement Analysis – Financial Results
Complete financial analysis of GRAIL, LLC (GRAL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GRAIL, LLC, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Raghav Productivity Enhancers Limited (RPEL.BO) Income Statement Analysis – Financial Results
- Takara Leben Co., Ltd. (8897.T) Income Statement Analysis – Financial Results
- Tokyo Chuo Auction Holdings Limited (1939.HK) Income Statement Analysis – Financial Results
- AxoGen, Inc. (AXGN) Income Statement Analysis – Financial Results
- WisdomTree Energy Enhanced (XMWK.DE) Income Statement Analysis – Financial Results
GRAIL, Inc. (GRAL)
About GRAIL, Inc.
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 93.11M | 55.55M | 14.61M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 188.72M | 172.00M | 114.62M | 0.00 | 10.31M | 14.08M |
| Gross Profit | -95.61M | -116.45M | -100.00M | 0.00 | -10.31M | -14.08M |
| Gross Profit Ratio | -102.69% | -209.63% | -684.39% | 0.00% | 0.00% | 0.00% |
| Research & Development | 338.75M | 329.58M | 460.21M | 192.91M | 154.58M | 203.38M |
| General & Administrative | 200.27M | 174.11M | 180.53M | 110.03M | 80.90M | 0.00 |
| Selling & Marketing | 162.29M | 122.33M | 53.53M | 13.47M | 7.68M | 0.00 |
| SG&A | 362.56M | 296.44M | 705.13M | 123.51M | 88.58M | 64.34M |
| Other Expenses | 718.47M | -238.00K | 0.00 | 0.00 | -1.82M | 0.00 |
| Operating Expenses | 1.42B | 626.01M | 1.17B | 318.26M | 243.16M | 267.72M |
| Cost & Expenses | 1.61B | 798.01M | 1.28B | 318.26M | 253.46M | 281.80M |
| Interest Income | 7.95M | 1.74M | 332.00K | 6.14M | 12.43M | 12.55M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 158.70M | 154.76M | 58.45M | 7.56M | 10.31M | 14.08M |
| EBITDA | -620.90M | -575.57M | -1.21B | -308.73M | -243.14M | -269.42M |
| EBITDA Ratio | -666.88% | -1,057.96% | -8,259.60% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.52B | -742.46M | -1.27B | -316.30M | -253.46M | -281.80M |
| Operating Income Ratio | -1,627.61% | -1,336.56% | -8,659.61% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.75M | 1.50M | 90.00K | 4.17M | 8.41M | 6.56M |
| Income Before Tax | -1.51B | -5.44B | -1.27B | -312.12M | -245.05M | -275.23M |
| Income Before Tax Ratio | -1,619.29% | -9,795.48% | -8,658.99% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -41.95M | -42.29M | -17.48M | 33.00K | -195.00K | 485.00K |
| Net Income | -1.47B | -5.40B | -1.25B | -312.16M | -244.86M | -275.72M |
| Net Income Ratio | -1,574.23% | -9,719.35% | -8,539.39% | 0.00% | 0.00% | 0.00% |
| EPS | -41.34 | -173.87 | -40.18 | -2.52 | -1.99 | -2.42 |
| EPS Diluted | -41.34 | -173.87 | -40.18 | -2.52 | -1.99 | -2.42 |
| Weighted Avg Shares Out | 31.05M | 31.05M | 31.05M | 123.67M | 123.19M | 114.14M |
| Weighted Avg Shares Out (Dil) | 31.05M | 31.05M | 31.05M | 123.67M | 123.19M | 114.14M |
World's biggest hedge fund flags the ‘holy grail' that may shield investors if U.S. stock rally crumbles
Karen Karniol-Tambour, co-chief investment officer at Bridgewater Associates, says valuations are much higher for U.S. stocks than they were when the bull run began.
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Dec. 3, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of...
GRAIL to Participate in Upcoming Investor Conferences
MENLO PARK, Calif. , Nov. 19, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will participate in the following investor conferences.
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
MENLO PARK, Calif. , Nov. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the...
GRAIL Inc. (GRAL) Q3 2024 Earnings Call Transcript
GRAIL Inc. (NASDAQ:GRAL ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Robert Ragusa - CEO & Director Aaron Freidin - Chief Financial Officer Joshua Ofman - President Harpal Kumar - President, International Business and...
GRAIL Reports Third Quarter 2024 Financial Results
Galleri Revenue Grew 52% Year-Over-Year to $25.4 Million Commercial Galleri Sales Surpassed 250,000 Tests Since Launch Cash Balance of $853.6 Million Provides Runway Into 2028 MENLO PARK, Calif. , Nov. 12, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare...
GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
MENLO PARK, Calif. , Nov. 4, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity MedTech,...
GRAIL to Announce Third Quarter 2024 Financial Results
MENLO PARK, Calif. , Oct. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2024...
Google: The Bullish Pivot Before The Earnings Grail
My previous bearish call on Google has aged well, with the stock losing around 14% of its value since July 10. I still believe that Google struggles to compete in the generative AI space, but this does not spell the...
GRAIL Presents Initial Results From REFLECTION Real-World Evidence Study of Galleri® Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer Conference
Study Participants from Veteran Affairs Sites Include a Diverse Population With Toxic Exposure MENLO PARK, Calif. , Oct. 23, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today...
Source: https://incomestatements.info
Category: Stock Reports